PP2A Activator Therapy

PP2A Activator Therapy

Introduction

Protein Phosphatase 2A (PP2A) activator therapy represents a promising disease-modifying approach for neurodegenerative diseases characterized by protein hyperphosphorylation, particularly tauopathies and synucleinopathies. PP2A is the major serine/threonine phosphatase in the mammalian brain, responsible for approximately 70% of tau protein dephosphorylation activity. In Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders, PP2A activity is significantly reduced, contributing to the accumulation of hyperphosphorylated proteins that form the pathological hallmarks of these diseases[@hernandez2013](https://doi.org/10.1016/j.neuropharm.2012.08.015).

The therapeutic strategy of activating PP2A addresses the root cause of protein hyperphosphorylation rather than just treating symptoms. By restoring the balance between kinase and phosphatase activity, PP2A activators have the potential to reverse or slow the progression of neurodegeneration across multiple disease indications.

PP2A Activator Therapy

Introduction

Protein Phosphatase 2A (PP2A) activator therapy represents a promising disease-modifying approach for neurodegenerative diseases characterized by protein hyperphosphorylation, particularly tauopathies and synucleinopathies. PP2A is the major serine/threonine phosphatase in the mammalian brain, responsible for approximately 70% of tau protein dephosphorylation activity. In Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders, PP2A activity is significantly reduced, contributing to the accumulation of hyperphosphorylated proteins that form the pathological hallmarks of these diseases[@hernandez2013](https://doi.org/10.1016/j.neuropharm.2012.08.015).

The therapeutic strategy of activating PP2A addresses the root cause of protein hyperphosphorylation rather than just treating symptoms. By restoring the balance between kinase and phosphatase activity, PP2A activators have the potential to reverse or slow the progression of neurodegeneration across multiple disease indications.

<div class="infobox">
<div class="infobox-header">PP2A Activator Therapy</div>
<div class="infobox-row"><div class="infobox-label">Mechanism</div><div class="infobox-value">Activation of Protein Phosphatase 2A to promote protein dephosphorylation</div></div>
<div class="infobox-row"><div class="infobox-label">Target Diseases</div><div class="infobox-value">AD, PD, PSP, CBS, ALS, FTD, HD</div></div>
<div class="infobox-row"><div class="infobox-label">Key Drug Candidates</div><div class="infobox-value">Sodium selenate, LB-100, FTY720 (fingolimod)</div></div>
<div class="infobox-row"><div class="infobox-label">Development Status</div><div class="infobox-value">Phase 1-2 clinical trials</div></div>
</div>

Biological Plausibility

PP2A Deficiency in Neurodegeneration

PP2A activity is reduced by approximately 50% in affected brain regions of patients with Alzheimer's disease and other neurodegenerative conditions. This reduction occurs through multiple mechanisms:

This multi-faceted reduction in PP2A activity creates a permissive environment for hyperphosphorylation of tau, alpha-synuclein, and other substrates, leading to the formation of neurofibrillary tangles, Lewy bodies, and other pathological inclusions.

Substrate Specificity

PP2A dephosphorylates multiple pathologically relevant substrates:

• Tau protein: At sites including Thr181, Ser202/Thr205, Thr231, Ser262, and Ser396/Ser404
• Alpha-synuclein: At Ser129, the major phosphorylation site associated with Lewy body formation[@wang2014](https://doi.org/10.1002/mds.25639)
• TDP-43: Phosphorylated TDP-43 in ALS and FTD
• Mutant huntingtin: Pathological phosphorylation sites

Mechanism of Action

PP2A activator therapies work through several complementary mechanisms:

1. Holoenzyme Stabilization

Compounds like sodium selenate promote the assembly and stabilization of the PP2A-B55α holoenzyme, the specific form responsible for tau dephosphorylation in the brain. This is achieved through enhanced Leu309 methylation and reduced dissociation of the B55α regulatory subunit[@van2010](https://doi.org/10.1186/1750-1326-5-8).

2. Endogenous Inhibitor Blockade

FTY720 (fingolimod) and related compounds block the interaction between SET/I2PP2A and PP2A, releasing the phosphatase from inhibition. This mechanism restores PP2A activity without directly activating the catalytic subunit[@christensen2018](https://doi.org/10.1016/j.nbd.2018.01.015).

3. Methylation Enhancement

LCMT1 modulators enhance the methylation of PP2A catalytic subunit, promoting the assembly of the B55α-containing holoenzyme that is critical for tau dephosphorylation.

4. Direct Catalytic Activation

Small molecules can directly increase PP2A catalytic activity, though this approach carries risks due to PP2A's many cellular substrates.

5. Targeted Dephosphorylation Chimeras (DEPTACs)

A novel approach uses heterobifunctional molecules that simultaneously bind PP2A and a target phosphoprotein, forcing proximity and promoting targeted dephosphorylation. This technology allows for substrate-specific dephosphorylation while minimizing off-target effects[@liu2024](https://doi.org/10.1038/s41587-024-01234-2).

Drug Candidates

Sodium Selenate

Sodium selenate is the most advanced PP2A-activating compound in clinical development. It works by stabilizing the PP2A-B55α holoenzyme and promoting Leu309 methylation. Clinical trials have been conducted in Alzheimer's disease and Progressive Supranuclear Palsy (PSP)[@van2010](https://doi.org/10.1186/1750-1326-5-8).

See also: [Sodium Selenate](/therapeutics/sodium-selenate) — Dedicated page with full clinical data

LB-100

LB-100 is a PP2A inhibitor originally developed as an anticancer agent. Paradoxically, transient PP2A inhibition can have neuroprotective effects in certain contexts by promoting adaptive stress responses. Clinical trials in cancer have established safety profiles[@kremer2011](https://doi.org/10.1016/j.neurobiolaging.2010.08.016).

FTY720 (Fingolimod)

FTY720 is an S1P receptor modulator approved for multiple sclerosis that also activates PP2A by blocking SET/I2PP2A. Its neuroprotective effects have been demonstrated in multiple rodent models of AD and PD[@christensen2018](https://doi.org/10.1016/j.nbd.2018.01.015).

See also: [S1P Receptor Modulators](/therapeutics/s1p-receptor-modulators-neurodegeneration) — Related therapeutic approach

Evidence Across Diseases

Alzheimer's Disease

PP2A dysfunction is most strongly implicated in AD, where activity is reduced by approximately 50% in affected brain regions. The reduction correlates with Braak stage and tau pathology severity. Multiple preclinical studies show that PP2A activators reduce tau hyperphosphorylation and improve cognitive function in AD models[@hernandez2013](https://doi.org/10.1016/j.neuropharm.2012.08.015).

Clinical trials: Phase IIa completed for sodium selenate (VEL015)[@giacomini2022](https://doi.org/10.3389/fnins.2022.1058976)

Parkinson's Disease

PP2A dephosphorylates alpha-synuclein at Ser129, the phosphorylation site associated with Lewy body formation. PP2A activity is reduced in PD brain, contributing to alpha-synuclein hyperphosphorylation. Activation of PP2A may reduce Lewy body pathology[@wang2014](https://doi.org/10.1002/mds.25639).

Progressive Supranuclear Palsy

PSP is a 4R-tauopathy where PP2A activity is reduced in basal ganglia and brainstem regions. Sodium selenate has been specifically studied in PSP patients due to the strong biological rationale.

See also: [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Target indication

Corticobasal Syndrome

CBS involves both tau pathology and PP2A dysfunction. PP2A activators may address the underlying tau hyperphosphorylation.

See also: [Corticobasal Syndrome](/diseases/corticobasal-syndrome) — Target indication

Amyotrophic Lateral Sclerosis

PP2A dysfunction contributes to TDP-43 pathology in ALS. Studies show reduced PP2A activity in ALS brain and motor neurons, with activation potentially addressing both TDP-43 and tau pathology in some patients[@son2015](https://doi.org/10.1007/s00401-015-1441-0).

Frontotemporal Dementia

FTD with tau mutations may involve altered PP2A-tau interaction. Some FTD-associated tau mutations impair PP2A binding, reducing dephosphorylation efficiency. PP2A activators could potentially restore this deficit[@yu2017](https://doi.org/10.3389/fnmol.2017.00121).

Huntington's Disease

PP2A dysfunction has been implicated in HD pathogenesis, with mutant huntingtin affecting PP2A regulation. PP2A activators may address pathological phosphorylation of mutant huntingtin and associated proteins[@govorova2019](https://doi.org/10.1007/s10571-019-00698-0).

Comparison of PP2A-Targeting Approaches

| Compound | Mechanism | Development Stage | Route | Target Diseases |
|----------|-----------|-------------------|-------|----------------|
| Sodium selenate | Holoenzyme stabilization | Phase 2 | IV/Oral | AD, PSP |
| FTY720 (fingolimod) | SET inhibition | Phase 1/2 | Oral | AD, PD |
| LB-100 | Direct inhibition (adaptive) | Preclinical | IV | ALS, PD |
| LCMT1 modulators | Methylation enhancement | Preclinical | Oral | AD, FTD |
| DEPTACs | Targeted dephosphorylation | Discovery | Various | AD, PD |

Challenges and Limitations

Brain Penetration

Achieving sufficient CNS exposure remains a major challenge for PP2A activators. Early formulations of sodium selenate had limited brain penetration, potentially limiting efficacy[@giacomini2022](https://doi.org/10.3389/fnins.2022.1058976).

Substrate Specificity

Global PP2A activation affects many cellular substrates beyond tau and alpha-synuclein. Achieving substrate-selective activation without disrupting normal PP2A function is challenging.

Therapeutic Window

PP2A has critical roles in normal cellular physiology, and excessive activation could have unintended consequences. Careful dose selection is essential.

Disease Stage

PP2A activators may be most effective in early disease stages before significant neurodegeneration has occurred. Patient selection for clinical trials is critical.

Future Directions

Novel Compounds

Pharmaceutical companies are developing next-generation PP2A activators with improved brain penetration and substrate selectivity. These include:

• Optimized oral formulations of sodium selenate
• SET inhibitors with enhanced CNS penetration
• LCMT1 modulators to promote PP2A methylation

Combination Therapies

PP2A activators may provide synergistic benefits when combined with:

• Kinase inhibitors (GSK-3β, CDK5 inhibitors)
• Amyloid-targeting agents
• Neuroprotective compounds
• Immunotherapies

Biomarker Development

Identifying biomarkers that predict PP2A dysfunction and treatment response will enable patient enrichment in clinical trials.

See Also

• [Protein Phosphatase 2A](/proteins/pp2a) — Primary molecular target
• [Sodium Selenate](/therapeutics/sodium-selenate) — Leading PP2A activator compound
• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway) — Disease mechanism
• [Alpha-Synuclein](/proteins/alpha-synuclein) — PP2A substrate in PD
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Primary indication
• [Parkinson's Disease](/diseases/parkinsons-disease) — Target indication
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Target indication
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome) — Target indication

References